Exact Sciences Corporation $EXAS Shares Sold by Osaic Holdings Inc.

Osaic Holdings Inc. decreased its stake in Exact Sciences Corporation (NASDAQ:EXAS) by 16.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,282 shares of the medical research company’s stock after selling 7,067 shares during the period. Osaic Holdings Inc.’s holdings in Exact Sciences were worth $1,874,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. True Wealth Design LLC increased its position in Exact Sciences by 951.8% in the second quarter. True Wealth Design LLC now owns 589 shares of the medical research company’s stock worth $31,000 after buying an additional 533 shares during the period. Country Trust Bank acquired a new position in shares of Exact Sciences during the second quarter valued at $32,000. Bessemer Group Inc. grew its position in shares of Exact Sciences by 1,980.6% during the second quarter. Bessemer Group Inc. now owns 645 shares of the medical research company’s stock worth $34,000 after acquiring an additional 614 shares during the last quarter. Bayforest Capital Ltd increased its holdings in shares of Exact Sciences by 95.8% in the 1st quarter. Bayforest Capital Ltd now owns 926 shares of the medical research company’s stock worth $40,000 after acquiring an additional 453 shares during the period. Finally, Parallel Advisors LLC lifted its position in Exact Sciences by 120.1% in the 2nd quarter. Parallel Advisors LLC now owns 799 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 436 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Analysts Set New Price Targets

EXAS has been the subject of several recent analyst reports. Jefferies Financial Group cut shares of Exact Sciences from a “buy” rating to a “hold” rating and upped their target price for the stock from $90.00 to $105.00 in a research report on Monday, November 24th. Wells Fargo & Company reissued an “equal weight” rating and issued a $105.00 price objective (up from $85.00) on shares of Exact Sciences in a report on Thursday, November 20th. Cowen downgraded Exact Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, November 25th. TD Cowen lowered Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. Finally, Leerink Partnrs lowered Exact Sciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 20th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, nineteen have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $85.00.

Exact Sciences Stock Performance

Shares of NASDAQ EXAS opened at $101.93 on Tuesday. Exact Sciences Corporation has a 1 year low of $38.81 and a 1 year high of $102.66. The company has a debt-to-equity ratio of 0.93, a quick ratio of 2.44 and a current ratio of 2.72. The stock has a fifty day moving average price of $86.23 and a two-hundred day moving average price of $63.86. The firm has a market cap of $19.31 billion, a P/E ratio of -19.16, a PEG ratio of 12.53 and a beta of 1.41.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.11. The business had revenue of $850.74 million during the quarter, compared to analyst estimates of $810.42 million. Exact Sciences had a positive return on equity of 1.67% and a negative net margin of 32.01%.The company’s revenue was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.21) earnings per share. Research analysts forecast that Exact Sciences Corporation will post -0.58 EPS for the current fiscal year.

Insider Transactions at Exact Sciences

In related news, Director James Edward Doyle sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of $60.00, for a total value of $120,000.00. Following the sale, the director directly owned 57,962 shares in the company, valued at $3,477,720. The trade was a 3.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Brian Baranick sold 2,858 shares of the stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $70.08, for a total transaction of $200,288.64. Following the sale, the executive vice president directly owned 22,368 shares of the company’s stock, valued at approximately $1,567,549.44. This represents a 11.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 9,858 shares of company stock valued at $695,289 in the last quarter. Insiders own 1.20% of the company’s stock.

Exact Sciences Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.